CompletedNCT01036061
Repeated GSK618334 doses for substance dependence: safety and drug levels
About this title
Read the official source — NCT01036061Medication studyAges 18–50United KingdomAddiction
Understand this study
Who was this study for?
This study was for healthy volunteers. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
- Listed locations
- LondonSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: September 28, 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 46
- Sponsor
- GlaxoSmithKline
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United Kingdom
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT01036061
- Official title
Show the full official title
A Placebo-controlled, Single Blind, Randomized Two Part Study Toinvestigate the Tolerability, Pharmacokinetics, and brainDopamine D3 Receptor Occupancy of Increasing Repeat Doses ofGSK618334 for up to 21 Days in Healthy Volunteers.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
London
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is GlaxoSmithKline.
Did this study involve medication?
Yes. The study involved medication, including GSK618334 Low Dose, GSK618334 PET subjects, GSK618334 Medium Dose and GSK618334 High Dose.
Who was this study for?
This study was for healthy volunteers. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
